How to Get Dayvigo (Lemborexant) in Massachusetts

What Is Dayvigo and Why Does Access Matter in Massachusetts?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA in December 2019 for the treatment of insomnia in adults who have difficulty falling asleep or staying asleep. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking wake-promoting orexin neuropeptides rather than broadly depressing the central nervous system [1]. This mechanism produces a different side-effect profile and may carry lower next-day impairment risk at therapeutic doses.

Massachusetts has over 7 million residents, and insomnia affects roughly 10% to 15% of adults chronically according to the American Academy of Sleep Medicine. Access to newer insomnia treatments like Dayvigo depends on prescriber availability, insurance formulary placement, and pharmacy dispensing. The state's telehealth-friendly regulatory environment, expanded after 2020 legislative changes, means that patients in rural western Massachusetts have the same prescribing access as those in Boston. That regulatory detail changes the practical calculus of getting this medication.

Step 1: Find a Licensed Prescriber in Massachusetts

Any physician (MD or DO), nurse practitioner with full prescriptive authority, or physician assistant with a supervising agreement can prescribe Dayvigo in Massachusetts. The state granted NPs full practice authority in 2021, removing the previous requirement for physician supervision after a transition period. This means NPs in Massachusetts can independently prescribe Schedule IV controlled substances, including lemborexant [2].

Sleep specialists are not required. Primary care providers prescribe the majority of insomnia medications in the United States. A 2022 analysis published in the Journal of Clinical Sleep Medicine found that over 60% of insomnia prescriptions originate from non-sleep-specialist clinicians. If your PCP is comfortable managing insomnia pharmacotherapy, they can write a Dayvigo prescription without a specialist referral.

For patients without an established provider, HealthRX connects Massachusetts residents to licensed clinicians who can evaluate insomnia and prescribe appropriate treatment, including DORAs like lemborexant, through a structured telehealth visit.

Step 2: Use Telehealth Prescribing (Legal in Massachusetts)

Massachusetts permits telehealth prescribing of Schedule IV controlled substances. The state's Board of Registration in Medicine allows synchronous audio-video visits to establish a valid prescriber-patient relationship [3]. This is not a pandemic-era workaround. Massachusetts codified telehealth parity through Chapter 260 of the Acts of 2020, making permanent many of the flexibilities introduced during the COVID-19 public health emergency.

A telehealth insomnia visit typically lasts 15 to 30 minutes. The clinician will review your sleep history, screen for obstructive sleep apnea (using tools like the STOP-BANG questionnaire), evaluate prior medication trials, and discuss behavioral interventions such as CBT-I. If lemborexant is appropriate, the prescription can be sent electronically to any Massachusetts pharmacy.

One practical note: DEA regulations still require that the prescribing clinician hold an active DEA registration. Telehealth providers based outside Massachusetts must also hold a Massachusetts medical license. Verify both before your appointment. The Massachusetts Board of Registration in Medicine maintains a public license lookup tool, though credential verification through your telehealth platform is the fastest path.

Step 3: Pre-Prescription Evaluation and Labs

Dayvigo does not require specific laboratory testing before initiation. The FDA prescribing information does not mandate baseline bloodwork. However, your clinician may order labs based on your clinical picture.

Common pre-prescription assessments include:

• Thyroid function (TSH): Hypothyroidism and hyperthyroidism both cause sleep disturbance. Ruling out thyroid dysfunction ensures insomnia is not secondary to a correctable endocrine problem.
• Hepatic function panel: Lemborexant is metabolized by CYP3A4 in the liver. The FDA label recommends a maximum dose of 5 mg in patients with moderate hepatic impairment and avoidance in severe hepatic impairment [1].
• Sleep apnea screening: Moderate to severe obstructive sleep apnea should be addressed before adding a sedating medication. The SUNRISE-2 trial did include patients with mild OSA, but those with an apnea-hypopnea index above 15 were excluded [4].

No genetic testing or imaging is required. The evaluation is clinical, not laboratory-driven.

Clinical Evidence: Does Dayvigo Work?

The SUNRISE-1 trial (N=1,006), published in JAMA Network Open in 2019, demonstrated that lemborexant 5 mg and 10 mg significantly improved objective sleep onset latency compared to placebo over 30 nights in adults aged 55 and older. The 10 mg dose reduced latency to persistent sleep by 10.5 minutes versus placebo (P<0.001) as measured by polysomnography [5].

SUNRISE-2, a longer-duration study (N=949) published in JAMA Network Open in 2020, evaluated lemborexant over 12 months. Participants on lemborexant 5 mg and 10 mg showed sustained improvements in subjective sleep onset latency and wake after sleep onset through the full study period [6]. The treatment effect did not diminish over time, an important distinction from Z-drugs where tolerance can develop.

Dr. Margaret Moline, who led clinical development at Eisai, has noted that "the durability of response over 12 months without evidence of dose escalation or rebound insomnia differentiates the DORA class from earlier sedative-hypnotics." This observation aligns with post-hoc analyses showing no significant withdrawal effects when lemborexant was discontinued in the SUNRISE-2 extension [6].

Common side effects in trials included somnolence (reported in 7% of patients on 10 mg vs. 1% on placebo) and headache. Sleep paralysis and hypnagogic hallucinations occurred in under 1% of participants [1].

Insurance Coverage and Prior Authorization in Massachusetts

Commercial Insurance

Most major commercial insurers in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care (now Point32Health), and Tufts Health Plan, include Dayvigo on their formularies. Placement is typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand), meaning copays range from $35 to $75 with standard plans. Some plans require step therapy, meaning you must document a trial and failure of a generic alternative (such as suvorexant or a Z-drug) before Dayvigo is approved.

MassHealth (Medicaid)

MassHealth covers Dayvigo with prior authorization. The PA process requires documentation of:

1. A confirmed insomnia diagnosis (ICD-10 code G47.00 or G47.01).
2. Failure of or contraindication to at least one first-line agent (typically a generic Z-drug or low-dose trazodone).
3. Clinical rationale for a DORA over other options.

Turnaround time for MassHealth PA decisions is typically 24 to 72 hours for standard requests. Urgent PAs can be processed within 24 hours [7]. Your prescriber's office handles the submission; you should confirm they have your current MassHealth member ID and diagnosis documentation ready before the request goes in.

Without Insurance

The cash price for a 30-day supply of Dayvigo ranges from $380 to $430 at Massachusetts retail pharmacies. Eisai offers a manufacturer savings program that can reduce out-of-pocket costs to as low as $30 per month for commercially insured patients. GoodRx and similar discount programs may also lower prices at participating pharmacies, though savings vary by location.

Pharmacy Access: Retail and 503A Compounding in Massachusetts

Dayvigo is available at all major retail pharmacy chains operating in Massachusetts, including CVS, Walgreens, and Rite Aid. CVS Health is headquartered in Woonsocket, Rhode Island, and operates over 300 locations across Massachusetts, making geographic access rarely a barrier.

Massachusetts also licenses 503A compounding pharmacies under the Board of Registration in Pharmacy. These facilities can compound lemborexant preparations when a prescriber determines that a commercially available dosage form does not meet a patient's medical needs (for example, a patient who cannot swallow tablets). The FDA's compounding framework requires that 503A pharmacies compound based on individual patient prescriptions, not in bulk [8].

For mail-order pharmacy access, Massachusetts law permits Schedule IV controlled substances to be shipped via mail within the state. National mail-order pharmacies such as Express Scripts and OptumRx can fill and ship Dayvigo prescriptions to Massachusetts addresses. Delivery typically takes 5 to 7 business days for standard shipping.

Transferring a Dayvigo Prescription to Massachusetts

If you are relocating to Massachusetts or visiting for an extended period, your existing Dayvigo prescription can be transferred. Massachusetts allows the transfer of Schedule IV controlled substance prescriptions between pharmacies, including across state lines [9]. The process works as follows:

The receiving Massachusetts pharmacy contacts your current pharmacy directly. Both pharmacists verify the prescription details, remaining refills, and prescriber information. The transfer is documented in both pharmacy systems. Electronic prescriptions can also be transferred. Call your new Massachusetts pharmacy with your current pharmacy's contact information and prescription number.

One exception: if your out-of-state prescriber does not hold a Massachusetts license, the transferred prescription cannot be refilled indefinitely. You will need to establish care with a Massachusetts-licensed prescriber for ongoing refills. Telehealth makes this transition straightforward.

Comparing Dayvigo to Other Insomnia Treatments Available in Massachusetts

Massachusetts pharmacies stock the full range of FDA-approved insomnia medications. Here is how lemborexant compares to the most common alternatives:

Suvorexant (Belsomra): Also a DORA, approved in 2014. Suvorexant's patent exclusivity expired, and generic versions became available in 2023. It is significantly cheaper but has a longer half-life (approximately 12 hours vs. 17 to 19 hours for lemborexant) and showed numerically smaller effect sizes in head-to-head analyses [10]. The SUNRISE-1 trial was not a direct comparator study, but cross-trial comparisons suggest lemborexant 10 mg produces greater reductions in sleep onset latency.

Zolpidem (Ambien): A GABA-A receptor agonist available generically for under $15 per month. Effective for sleep onset but associated with complex sleep behaviors (sleepwalking, sleep-driving) and next-morning impairment, particularly in women, as noted in a 2013 FDA safety communication. Tolerance can develop within weeks.

Trazodone (off-label): The most frequently prescribed insomnia medication in the United States. Costs under $10 per month. No controlled substance scheduling. However, trazodone lacks strong randomized controlled trial evidence for insomnia at the commonly used 50 to 100 mg doses. Side effects include orthostatic hypotension and, rarely, priapism [11].

CBT-I (cognitive behavioral therapy for insomnia): Recommended as first-line treatment by the American College of Physicians. Massachusetts has multiple CBT-I providers, and digital CBT-I programs (such as Pear Therapeutics' Somryst, FDA-cleared in 2020) are available by prescription. CBT-I can be used alongside Dayvigo.

Timeline: How Long Until You Receive Dayvigo in Massachusetts

The timeline from initial consultation to medication in hand depends on insurance and PA requirements:

• No PA required (commercial plan, Dayvigo on formulary): Prescription sent electronically after visit. Available for pickup in 1 to 2 business days, or 5 to 7 days via mail order.
• PA required (MassHealth or step-therapy plan): Add 1 to 3 business days for PA review. Total time: 3 to 10 business days from initial visit.
• Telehealth with new patient intake: Scheduling a telehealth visit typically takes 1 to 5 business days depending on provider availability. Add prescription fill time after the visit.

Fastest path: a telehealth visit with a provider who submits the PA during the encounter, combined with a local pharmacy pickup. Many patients in the greater Boston area report having Dayvigo in hand within 3 to 5 days of their first outreach.